Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data

@inproceedings{Zamarin2015ReplicationCompetentVA,
  title={Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data},
  author={Dmitriy Zamarin and Sari Pesonen},
  booktitle={Human gene therapy},
  year={2015}
}
Replication-competent (oncolytic) viruses (OV) as cancer immunotherapeutics have gained an increasing level of attention over the last few years while the clinical evidence of virus-mediated antitumor immune responses is still anecdotal. Multiple clinical studies are currently ongoing and more immunomonitoring results are expected within the next five years. All viruses can be recognized by the immune system and are therefore potential candidates for immune therapeutics. However, each virus… CONTINUE READING

Figures and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

A Blueprint to Advance Colorectal Cancer Immunotherapies.

  • Cancer immunology research
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 92 REFERENCES

Intratumoral ONCOS-102 shapes the tumor microenvironment in last line rafractory solid tumor patients

S Pesonen, T Joensuu, E Jäger
  • CRI Annual International Cancer Immunotherapy Symposium,
  • 2014
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2006
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 2 EXCERPTS